Valo Health to list on Nasdaq via back door

10 June 2021
valo_big

Valo Health has announced its intention to list as a publicly-traded company, with a significant investment from backers including Khosla Ventures, Koch Disruptive Technologies and Flagship Pioneering.

Rather than go through a traditional initial public offering (IPO), the company will merge with a so-called special purpose acquisition company (SPAC), formed by Khosla Ventures.

The approach provides rapid access to funds and speeds up the process of going public, while offering more control over the terms of the deal.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology